Zimmer Biomet delivered a solid QQ2 2024, reinforcing a multi-year growth trajectory across a diversified portfolio. Excluding FX, Q2 revenue rose 5.6% y/y to $1.94 billion, aided by strength in S.E.T., international markets, and a robust ROSA enabling technologies ecosystem. Management emphasized ongoing execution on the long-range plan: mid-single digit revenue growth, EPS growth of at least 1.5x revenue, and free cash flow outpacing EPS by at least 100 bps, with improvements in operating leverage supported by a restructuring program and productivity initiatives. The company highlighted meaningful progress in hip portfolio restoration (Z1 triple-taper stem, HAMMR surgical impactor, and advanced navigation) and asserted a pathway to regaining hip market share, complemented by a broader ROSA roadmap and new navigation modalities via OrthoGrid and Hip Insights partnerships. In the near term, Zimmer Biomet reiterated its 2024 guidance (5-6% constant-currency revenue growth; $8.00-$8.15 in adjusted EPS; $1.05b-$1.1b free cash flow) despite a higher USD headwind, signaling confidence in a stronger H2 cadence and continued ROSA penetration across geographies.